Aprogen Biologics
에이프로젠바이오로직스 · 003060
Health Care Pharmaceuticals · KOSPI
Market cap US$29.5M (₩40.6B)
Overview
Aprogen Biologics makes prescription medicines, both conventional small-molecule drugs and biologic medicines (complex drugs derived from living cells), and distributes them to wholesalers, hospitals, clinics, and pharmacies across Korea.
Listed on KOSPI, Korea's main stock exchange, it operates through subsidiaries that handle distribution and, more recently, semiconductor equipment parts. Its pharmaceutical business is divided into a generics segment, producing drugs for cardiovascular, central-nervous-system, digestive, and metabolic conditions, and a biologics segment focused on antibody medicines.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$63.3M
- FY2024US$48.8M
- FY2025US$53.1M
Operating profit
- FY2023−US$41.7M
- FY2024−US$38.3M
- FY2025−US$43.7M
Net income
- FY2023−US$83.6M
- FY2024−US$76.1M
- FY2025−US$122M
Key ratios (FY2025)
Why it matters
Its biologics manufacturing facility is located in Osong, Chungbuk, and uses a continuous perfusion-culture process to produce antibody drug substances at large scale.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?